Cover Image
市场调查报告书

美国的体外诊断(IVD)市场成长机会

Growth Opportunities in the US In Vitro Diagnostics (IVD) Market, Forecast to 2021

出版商 Frost & Sullivan 商品编码 509470
出版日期 内容信息 英文 118 Pages
商品交期: 最快1-2个工作天内
价格
Back to Top
美国的体外诊断(IVD)市场成长机会 Growth Opportunities in the US In Vitro Diagnostics (IVD) Market, Forecast to 2021
出版日期: 2017年05月23日 内容信息: 英文 118 Pages
简介

本报告提供美国的体外诊断(IVD)市场调查,提供市场基本结构和各市场区隔的市场趋势,收益,市场占有率的分析与预测,成长机会的考察,竞争情形和主要企业等系统性信息。

第1章 摘要整理

第2章 市场概要

  • 市场定义
  • 市场促进·阻碍因素
  • 考虑PAMA的原因(PAMA)
  • PAMA法规的影响
  • 实施的行动计划
  • PAMA的影响预测
  • CLSF(临床检验标准费用表)及医疗编码
  • IVD产业的价值链
  • 体外诊断的技术趋势

第3章 愿景与策略:新的成长机会

  • 体外诊断产业的生态系统变化
  • 前3名市场区隔的供应商成长机会
  • 从宏观转移到微观
  • 5大成长机会
  • 成长机会(1)巨量数据的利用
  • 成长机会(2)液态切片(液体细胞诊断)及搭配诊断(CDx)
  • 成长机会(3)分子POC(照护现场)检验
  • 成长机会(4)消费者直接耦合型(DTC)检验
  • 成长机会(5)药理基因(PGx)检验
  • 美国的体外诊断(IVD)市场预测

第4章 市场预测

  • 体外诊断(IVD)的全体市场:收益预测
  • 收益预测:各市场区隔
  • 收益成长率:各市场区隔
  • 收益率的预测:各市场区隔

第5章 竞争分析

  • 参与企业的策略
  • 竞争矩阵
  • 销售额分析:各市场区隔
  • 美国市场前13名企业
  • 市场排行榜
  • 主要趋势
  • 追加的投资机会

第6章 血液学市场区隔的明细

  • 机会与课题
  • 收益预测
  • 市场占有率分析
  • 关注的产品

第7章 血液凝固市场区隔的明细

  • 机会与课题
  • 收益预测
  • 市场占有率分析
  • 关注的产品

第8章 照护现场(POT)检验市场区隔的明细

  • 机会与课题
  • 收益预测
  • 市场占有率分析
  • 关注的产品

第9章 分子诊断市场区隔的明细

  • 机会与课题
  • 收益预测
  • 市场占有率分析
  • 关注的产品

第10章 细胞诊断市场区隔的明细

  • 机会与课题
  • 收益预测
  • 市场占有率分析
  • 关注的产品

第11章 血糖自我检测(SMBG)市场区隔的明细

  • 机会与课题
  • 收益预测
  • 市场占有率分析
  • 关注的产品

第12章 临床微生物学市场区隔的明细

  • 机会与课题
  • 收益预测
  • 市场占有率分析
  • 关注的产品

第13章 免疫化学市场区隔的明细

  • 机会与课题
  • 收益预测
  • 市场占有率分析
  • 关注的产品

第14章 总论

  • 汇整与未来展望
  • 免责声明

第15章 附录

目录
Product Code: K18C-52

US IVD Market Witnesses Pricing Fluctuations Due to the PAMA Regulation

The In Vitro Diagnostics (IVD) landscape in the United States is extremely dynamic, with a high level of merger and acquisition activity with many high-value deals still pending. Both clinical laboratories and manufacturers are increasingly vying for smaller specialized niche technology companies to increase their market share. Molecular point of care testing (POCT) and liquid biopsy continue to attract investment opportunities from private equity and venture capitalists. The new government in the United States aims to provide a retail-like experience for healthcare services. As a result, innovative and clinically vetted direct to consumer (DTC) diagnostic testing services are expected to thrive. Partnerships with non-healthcare (HC) companies are expected to empower core diagnostic companies with artificial intelligence (AI) and big data capabilities are on the rise. Given these market trends, it is important to understand the market dynamics to remain competitive and successful in the IVD market in the United States of America.

Research Scope:

The key objectives of this growth opportunity study are to track the changes in the IVD market landscape in the United States for 2016-2021. The study aims to identify growth segments and disruptive companies to invest into. Further, the study provides an in-depth revenue and market share analysis of over 8 segments within the IVD landscape: POCT, tissue diagnostics, self-monitoring blood glucose meter (SMBG), hemostasis, hematology, clinical chemistry, microbiology, immunochemistry, and molecular diagnostics. The study highlights industry challenges, growth drivers, restraints, competitive developments, mergers and acquisition, and investment opportunities. It also discusses the impact of Protecting Access to Medicare Act (PAMA), identifies transforming business models, and makes strategic recommendations to understand the dynamics of the US IVD market. The study also covers key trends and growth opportunities, game-changing companies, disruptive technologies and transforming business models, as well as strategic recommendations.

Key Questions this Study will Answer:

  • 1. What are some of the current issues that concern the US IVD industry? How would these impact the different stakeholders in the healthcare landscape?
  • 2. Which are the major segments of growth and why should you invest in them?
  • 3. How to identify partners outside the conventional IVD realm?
  • 4. How can big data support the growth of the IVD industry?
  • 5. What are some of the newer products to watch in 2017 and beyond?
  • 6. Which companies are categorized as early disruptors in this space? Who are the possible candidates to acquire, invest in, and help grow your business?

Table of Contents

1. EXECUTIVE DASHBOARD

  • Purpose of this Experiential Study
  • 5 Step Process to Transformational Growth
  • Scope and Segmentation
  • Market Highlights
  • Strategic Imperatives for Suppliers and Laboratories
  • 6 Big Growth Themes for US IVD Industry
  • Key Questions this Study will Answer

2. GROWTH ENVIRONMENT-MARKET OVERVIEW

  • Market Definition and Segments Covered
  • Market Drivers and Restraints
  • Reasons for Considering PAMA
  • Impact of the PAMA Regulations
  • Proposed Timeline for Implementation
  • Foreseeing the Effects of PAMA
  • CLFS Rate/Code Determination
  • Value Chain of IVD Industry
  • Value Chain of IVD Industry (continued)
  • Value Chain of IVD Industry (continued)
  • Key Disruptive IVD Concepts to Impact Healthcare by 2021
  • Snapshot of Growth Technologies in In-vitro Diagnostics Market

3. VISION AND STRATEGY-EMERGING GROWTH OPPORTUNITIES

  • Transformation in the IVD Industry Ecosystem-2016
  • Growth Opportunities for Suppliers in Top 3 Segments
  • Macro to Micro Visioning
  • 5 Major Growth Opportunities
  • Opportunity 1-Use of Big Data
  • Opportunity 2-Liquid Biopsy and CDx
  • Opportunity 3-Molecular POCT
  • Opportunity 4-Direct-to-Consumer Testing
  • Opportunity 5-PGx Testing
  • Top Predictions for the US IVD Market

4. TOTAL MARKET FORECASTS

  • Total IVD Market-Revenue Forecast
  • Revenue Forecast by Segment
  • Revenue Growth Rate by Segment
  • Percent Revenue Forecast by Segment
  • Overall US IVD Market Share
  • Overall US IVD Market Share Analysis

5. COMPETITIVE ANALYSIS

  • 2016 IVD Market Participant Strategies
  • 2016 IVD Market Participant Strategies (continued)
  • Competitor IVD Matrix
  • Segment Sales Analysis
  • Segment Sales Analysis (continued)
  • Top 13 Companies-US IVD Market
  • Competitor Segment Ranking Matrix
  • Notable Activities
  • Notable Activities (continued)
  • Venture Radar-Additional Investment Opportunities

6. HEMATOLOGY SEGMENT BREAKDOWN

  • Opportunities and Challenges-Hematology
  • Revenue Forecast-Hematology
  • Market Share Analysis-Hematology
  • Products to Watch in 2017

7. HEMOSTASIS SEGMENT BREAKDOWN

  • Opportunities and Challenges-Hemostasis
  • Revenue Forecast-Hemostasis
  • Market Share Analysis-Hemostasis
  • Products to Watch in 2017

8. POCT SEGMENT BREAKDOWN

  • Opportunities and Challenges-POCT
  • Revenue Forecast-POCT
  • Market Share Analysis-POCT
  • Products to Watch in 2017

9. MOLECULAR DIAGNOSTICS SEGMENT BREAKDOWN

  • Opportunities and Challenges-Molecular Diagnostics
  • Revenue Forecast-Molecular Diagnostics
  • Market Share Analysis-Molecular Diagnostics
  • Products to Watch in 2017

10. TISSUE DIAGNOSTICS SEGMENT BREAKDOWN

  • Opportunities and Challenges-Tissue Diagnostics
  • Revenue Forecast-Tissue Diagnostics
  • Market Share Analysis-Tissue Diagnostics
  • Products to Watch in 2017
  • Reimbursement Analysis for Key AP Codes

11. SMBG SEGMENT BREAKDOWN

  • Opportunities and Challenges-SMBG
  • Revenue Forecast-SMBG
  • Market Share Analysis-SMBG
  • Product to Watch in 2017

12. CLINICAL MICROBIOLOGY SEGMENT BREAKDOWN

  • Opportunities and Challenges-Clinical Microbiology
  • Revenue Forecast-Clinical Microbiology
  • Market Share Analysis-Clinical Microbiology
  • Products to Watch in 2017

13. IMMUNOCHEMISTRY SEGMENT BREAKDOWN (INCLUDES REVENUES FOR IMMUNOSSAY, CLINICAL CHEMISTRY, AND URINALYSIS)

  • Opportunities and Challenges-Immunochemistry
  • Revenue Forecast-Immunochemistry
  • Market Share Analysis-Immunochemistry
  • Market Share Analysis (continued)
  • Competitor Customer Coverage

14. LAST WORD

  • Key Conclusions and Future Outlook
  • Legal Disclaimer

15. APPENDIX (CAPITAL PRICING AND INSTALLED BASE)

  • Installed Base and Pricing Analysis-Hematology
  • Installed Base and Pricing Analysis-Hematology (continued)
  • Installed Base and Pricing Analysis-Hemostasis
  • Pricing Analysis-NGS
  • Pricing Analysis-Thermal Cyclers
  • Pricing Analysis-Microarrays
  • Pricing Analysis-Tissue Diagnostics
  • Pricing Analysis-Tissue Diagnostics (continued)
  • Pricing Analysis-Tissue Diagnostics (continued)
  • Pricing Analysis-Tissue Diagnostics (continued)
  • Installed Base and Pricing Analysis-Immunoassay Systems
  • Installed Base and Pricing Analysis-Immunoassay Systems (continued)
  • Installed Base and Pricing Analysis-Immunoassay Systems (continued)
  • Installed Base and Pricing Analysis-Immunoassay Systems (continued)
  • Installed Base and Pricing Analysis-Immunoassay Systems (continued)
  • Installed Base and Pricing Analysis-Chemistry Analyzers
  • Pricing Analysis-Automated Urine Analyzers
  • Key Abbreviations
  • List of Other Companies Includes
Back to Top